Clonazepam, the active ingredient in Pase, is a benzodiazepine with anticonvulsant, sedative, muscle-relaxing, and anxiolytic properties. Its primary action involves enhancing GABAergic neurotransmission at inhibitory synapses. By binding to GABA receptors, clonazepam increases the affinity for GABA, enhancing chloride ion flux and inhibitory effects on neurons.
Additionally, clonazepam affects serotonin pathways and suppresses various paroxysmal EEG activities, including those seen in absence seizures, slow spike waves, and other focal or generalized epileptic discharges. These properties make it effective in treating both generalized and focal epilepsies.
100% Genuine Products, Guaranteed
Safe & Secure Payments, Always
Fast, Secure & Efficient Delivery
Proper Packaging
Show More
Cilnidipine, a dihydropyridine calcium-channel blocker, acts by binding to L-type voltage-dependent calcium channels, reducing calcium ion (Ca²⁺) influx into vascular smooth muscle cells. This leads to muscle relaxation and vasodilation. Cilnidipine also inhibits Ca²⁺ influx via N-type calcium channels in sympathetic nerve membranes, reducing norepinephrine release and potentially preventing reflexive heart rate increases after blood pressure reduction.
Do not consume alcohol while taking Pase 0.5 as it may provoke seizures or fits and may worsen side effects possibly leading to severe sedation.
Pase 0.5 is generally not recommended for use in pregnant women unless considered necessary. Consult your doctor before taking it.
Pase 0.5 is generally not recommended for use in breastfeeding women as it may pass through the breast milk and may cause drowsiness and feeding difficulties. Consult your doctor before taking Pase 0.5.
Pase 0.5 may cause drowsiness or sleepiness which can affect your ability to drive and operate machines. Do not drive or operate any machines while taking Pase 0.5.
Pase 0.5 should be used with caution in patients with severe kidney disease. Consult your doctor before taking it.
Pase 0.5 is not recommended for use in patients with severe liver disease. It should be used with caution in patients with mild to moderate liver disease. Consult your doctor before taking it.
Symptoms: Drowsiness, ataxia, dysarthria, nystagmus, respiratory depression, hypotension, coma, or cardiac arrest (severe cases).
Treatment: Supportive measures, monitoring vitals, administering activated charcoal (if within 1-2 hours), and flumazenil (a benzodiazepine antagonist) under strict medical supervision.
Pase’s long-term effectiveness (beyond 9 weeks) has not been systematically studied in controlled trials. Physicians should periodically reassess its long-term usefulness for individual patients.
Take medication only as advised by a registered physician.
Adults (Seizures):
Adults (Panic Disorder):
Pediatric Patients (Seizures):
Pregnancy:
Lactation:
Store in a dry place, away from light and heat. Keep out of reach of children.
Disclaimer:
ePharma sole intention is to ensure that its consumers get proper
information as musch as possible. Although we do not guarantee the
accuracy and the completeness of the information that provided and
here information is for informational purposes only.
The information contained herein should NOT be used as a substitute
for the advice of a qualified physician. This may not cover
everything about particular health conditions,
lab tests, medicines, all possible side effects, drug interactions,
warnings, alerts, etc. Please consult your healthcare professional
and discuss all your queries related to any disease or medicine. We
intend to support, not replace, the doctor-patient relationship.